"Alendronate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.
Descriptor ID |
D019386
|
MeSH Number(s) |
D02.705.429.500.100
|
Concept/Terms |
Alendronate- Alendronate
- Aminohydroxybutane Bisphosphonate
- Bisphosphonate, Aminohydroxybutane
- 4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate
- 4 Amino 1 Hydroxybutylidene 1,1 Biphosphonate
Alendronate Sodium- Alendronate Sodium
- Sodium, Alendronate
- Alendronate Monosodium Salt, Trihydrate
|
Below are MeSH descriptors whose meaning is more general than "Alendronate".
Below are MeSH descriptors whose meaning is more specific than "Alendronate".
This graph shows the total number of publications written about "Alendronate" by people in this website by year, and whether "Alendronate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2001 | 1 | 0 | 1 |
2003 | 1 | 0 | 1 |
2004 | 1 | 0 | 1 |
2017 | 0 | 1 | 1 |
2019 | 2 | 0 | 2 |
2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Alendronate" by people in Profiles.
-
Patterns of Osteoporosis Medications Selection After Drug Holiday or Continued Therapy: A Real-World Experience. Endocr Pract. 2022 Oct; 28(10):1078-1085.
-
Reply. J Allergy Clin Immunol. 2019 09; 144(3):873-874.
-
Loss of bronchoprotection with ICS plus LABA treatment, ?-receptor dynamics, and the effect of alendronate. J Allergy Clin Immunol. 2019 08; 144(2):416-425.e7.
-
Role of subchondral bone properties and changes in development of load-induced osteoarthritis in mice. Osteoarthritis Cartilage. 2017 12; 25(12):2108-2118.
-
Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties. J Orthop Res. 2004 May; 22(3):465-71.
-
Canine cancellous bone microarchitecture after one year of high-dose bisphosphonates. Calcif Tissue Int. 2003 Jun; 72(6):737-44.
-
Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001 Jan; 44(1):202-11.